DE69925894D1 - Verwendung von equiner-Herpes-Virus-typ-4-Thymidin-Kinase und einen Nucleosidanalog ausgewählt von Ganciclovir und Acyclovir zur Tötung von proliferativen Humanzellen - Google Patents
Verwendung von equiner-Herpes-Virus-typ-4-Thymidin-Kinase und einen Nucleosidanalog ausgewählt von Ganciclovir und Acyclovir zur Tötung von proliferativen HumanzellenInfo
- Publication number
- DE69925894D1 DE69925894D1 DE69925894T DE69925894T DE69925894D1 DE 69925894 D1 DE69925894 D1 DE 69925894D1 DE 69925894 T DE69925894 T DE 69925894T DE 69925894 T DE69925894 T DE 69925894T DE 69925894 D1 DE69925894 D1 DE 69925894D1
- Authority
- DE
- Germany
- Prior art keywords
- nucleoside analog
- thymidine kinase
- virus type
- herpes virus
- ganciclovir
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000701089 Equid alphaherpesvirus 4 Species 0.000 title abstract 3
- 102000006601 Thymidine Kinase Human genes 0.000 title abstract 3
- 108020004440 Thymidine kinase Proteins 0.000 title abstract 3
- 239000002777 nucleoside Substances 0.000 title abstract 3
- 150000003833 nucleoside derivatives Chemical class 0.000 title abstract 3
- 230000002062 proliferating effect Effects 0.000 title abstract 2
- 229960004150 aciclovir Drugs 0.000 title 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 title 1
- 229960002963 ganciclovir Drugs 0.000 title 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 title 1
- 210000005260 human cell Anatomy 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 abstract 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000009877 rendering Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99400964A EP1046400B1 (de) | 1999-04-20 | 1999-04-20 | Verwendung von equiner-Herpes-Virus-typ-4-Thymidin-Kinase und einen Nucleosidanalog ausgewählt von Ganciclovir und Acyclovir zur Tötung von proliferativen Humanzellen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69925894D1 true DE69925894D1 (de) | 2005-07-28 |
| DE69925894T2 DE69925894T2 (de) | 2006-05-11 |
Family
ID=8241950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69925894T Expired - Lifetime DE69925894T2 (de) | 1999-04-20 | 1999-04-20 | Verwendung von equiner-Herpes-Virus-typ-4-Thymidin-Kinase und einen Nucleosidanalog ausgewählt von Ganciclovir und Acyclovir zur Tötung von proliferativen Humanzellen |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1046400B1 (de) |
| JP (1) | JP2001031587A (de) |
| AT (1) | ATE298245T1 (de) |
| CA (1) | CA2306355A1 (de) |
| DE (1) | DE69925894T2 (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5757608B2 (ja) * | 2009-11-18 | 2015-07-29 | 国立大学法人 千葉大学 | 遺伝子スイッチおよび遺伝子回路の選択方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9014951D0 (en) * | 1990-07-06 | 1990-08-29 | Univ Glasgow | Equine herpesvirus-4 tk vaccine |
| FR2716459B1 (fr) * | 1994-02-22 | 1996-05-10 | Univ Paris Curie | Système hôte-vecteur utilisable en thérapie génique. |
-
1999
- 1999-04-20 AT AT99400964T patent/ATE298245T1/de not_active IP Right Cessation
- 1999-04-20 DE DE69925894T patent/DE69925894T2/de not_active Expired - Lifetime
- 1999-04-20 EP EP99400964A patent/EP1046400B1/de not_active Expired - Lifetime
-
2000
- 2000-04-19 CA CA002306355A patent/CA2306355A1/en not_active Abandoned
- 2000-04-20 JP JP2000159149A patent/JP2001031587A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1046400B1 (de) | 2005-06-22 |
| CA2306355A1 (en) | 2000-10-20 |
| DE69925894T2 (de) | 2006-05-11 |
| EP1046400A1 (de) | 2000-10-25 |
| ATE298245T1 (de) | 2005-07-15 |
| JP2001031587A (ja) | 2001-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Franceschi et al. | Gene therapy for bone formation: in vitro and in vivo osteogenic activity of an adenovirus expressing BMP7 | |
| CY1107121T1 (el) | Ρυθμιση διαφοροποιησης αιματοποιητικων βλαστικων κυτταρων με τη χρηση ανθρωπινων μεσυγχυματικων βλαστικων κυτταρων | |
| PT1062321E (pt) | Utilizacoes para celulas estaminais mesenquimais humanas nao autologas | |
| Garmyn et al. | Effect of aging and habitual sun exposure on the genetic response of cultured human keratinocytes to solar-simulated irradiation | |
| DE69230993D1 (de) | Rekombinante viren vektoren zur expression in muskelzellen | |
| ES2144414T3 (es) | Control de la expresion de un gen por medio de una radiacion ionizante. | |
| WO2000006705A3 (de) | Genetisch modifizierte cd34-negative, adhärent wachsende stammzellen und deren verwendung in der gentherapie | |
| DK478786A (da) | Cystein-forarmede muteiner af biologisk aktive humantumornekrosefaktorproteiner | |
| BR9914643A (pt) | Vetores adeno-associados para expressão dofator viii por células alvo | |
| JP2002518990A5 (de) | ||
| SE9002589D0 (sv) | Neutrofil-aktiverande peptid-2 | |
| ATE391175T1 (de) | Multidrug resistenz gen | |
| Nilsen-Hamilton et al. | Stimulation of the release of two glycoproteins from mouse 3T3 cells by growth factors and by agents that increase intralysosomal pH | |
| DE69830251D1 (de) | Langes pentraxin ptx3 enthaltende pharmazeutische zusammensetzungen | |
| DE69434315D1 (de) | Dap-2 tumorsupressorgen, durch sie kodierte protein und verwendung besagter gen und protein | |
| DE69925894D1 (de) | Verwendung von equiner-Herpes-Virus-typ-4-Thymidin-Kinase und einen Nucleosidanalog ausgewählt von Ganciclovir und Acyclovir zur Tötung von proliferativen Humanzellen | |
| ATE310828T1 (de) | Implantat und vektor zur behandlung von erworbenen krankheiten | |
| Takeshita et al. | Effect of interleukin‐1β on gene expressions and functions of fibroblastic cells derived from human periodontal ligament | |
| Singh et al. | Tissue engineering: the biologic modifiers in periodontal regeneration | |
| ATE317905T1 (de) | Arzneimittel enthaltend wenigstens einen teil des ul84-proteins des cytomegalovirus, verwendung von polypeptiden entsprechend der aminosäuresequenz des ul84-proteins und verfahren zur einführung von ul84 in zielzellen | |
| Wright et al. | EX VIVO GENE THERAPY BASED ON HUMAN WHITE BLOOD CELLS (WBC) INDUCE BONE GROWTH IN VIVO | |
| Enk et al. | Nonmonoclonal PTCH gene mutations in psoralen plus UVA-associated basal cell carcinomas | |
| Green et al. | Quantitative comparison of mesoderm inducing factors in xenopus | |
| JP2001031587A5 (de) | ||
| David et al. | Molecular studies on embryonic induction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |